Lo Andrew 4
4 · BridgeBio Pharma, Inc. · Filed Nov 19, 2025
Insider Transaction Report
Form 4
Lo Andrew
Director
Transactions
- Sale
Common Stock
2025-11-17$67.06/sh−3,798$254,679→ 14,089 total - Sale
Common Stock
2025-11-18$66.05/sh−30,993$2,047,057→ 50,583 total(indirect: By Andrew W. Lo and Nancy N. Lo JTWROS) - Sale
Common Stock
2025-11-17$66.63/sh−36,801$2,451,914→ 17,887 total - Sale
Common Stock
2025-11-18$65.23/sh−24,007$1,566,013→ 81,576 total(indirect: By Andrew W. Lo and Nancy N. Lo JTWROS)
Footnotes (4)
- [F1]Represents the weighted average sale price of the shares sold from $65.975 to $66.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F2]Represents the weighted average sale price of the shares sold from $66.975 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]Represents the weighted average sale price of the shares sold from $64.58 to $65.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F4]Represents the weighted average sale price of the shares sold from $65.58 to $66.52 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.